Table 1.
Baseline demographics and clinical characteristics of the patients (N = 235).
| Characteristics | Number (%)/mean ± S.D./median [IQR] |
|---|---|
| Age (year) | 51.3 ± 12.0 |
| Gender (men/women) | 200 (85.1)/35 (14.9) |
| Etiology (HBV/HCV/other) | 201 (85.5)/9 (3.8)/25 (10.6) |
| Child-pugh (A/B) | 226 (96.2)/9 (3.8) |
| ECOG (0/1) | 121 (51.5)/114 (48.5) |
| BCLC (A/B/C) | 13 (5.5)/70 (29.8)/152 (64.7) |
| Previous treatments (yes/no) | 20 (8.5)/215 (91.5) |
| Tumor burden | |
| Tumor size (cm) | 8.5 [6.0–12.3] |
| No. of HCC nodules | 1 [1-2] |
| PVTT (absent/present) | 166 (70.6)/69 (29.4) |
| EHS (absent/present) | 173 (73.6)/62 (26.4) |
| AFP (ng/mL) | 414.5 [12.6–9380.5] |
| Baseline laboratory values | |
| Leukocyte (×10E9/L) | 5.8 ± 2.7 |
| Hemoglobin (g/L) | 137.3 ± 20.5 |
| Platelets (×10E9/L) | 144.3 ± 78.6 |
| INR | 1.11 ± 0.13 |
| ALT (U/L) | 46.0 ± 31.6 |
| AST (U/L) | 61.0 ± 43.9 |
| Albumin (g/L) | 39.3 ± 5.2 |
| Total bilirubin (μmol/L) | 17.5 ± 8.8 |
| Urea nitrogen (mmol/L) | 5.0 ± 1.6 |
| Serum creatinine (μmol/L) | 83.6 ± 16.6 |
Abbreviations: S.D., standard deviation; IQR, inter quartile range; HBV, hepatitis B virus; HCV, hepatitis C virus; ECOG, Eastern cooperative oncology group; BCLC, Barcelona clinic liver cancer; PVTT, portal vein tumor thrombus; EHS, extrahepatic spreading; AFP, alpha-fetoprotein; INR, International normalized ratio; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase.